Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

71.41
-0.9250-1.28%
Volume:547.67K
Turnover:39.29M
Market Cap:11.80B
PE:-30.00
High:72.30
Open:71.84
Low:70.92
Close:72.33
52wk High:86.74
52wk Low:23.95
Shares:165.19M
Float Shares:164.00M
Volume Ratio:0.83
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3800
EPS(LYR):-2.3812
ROE:-70.80%
ROA:-7.31%
PB:24.12
PE(LYR):-29.99

Loading ...

Ionis Pharmaceuticals: Strong Growth Potential and Strategic Advancements Drive Buy Rating

TIPRANKS
·
Oct 30, 2025

Ionis Pharmaceuticals reports Q3 EPS (80c), consensus ($1.05)

TIPRANKS
·
Oct 29, 2025

GUIDANCE: (IONS) Ionis Pharmaceuticals Expects Full Year 2025 Total Revenue Range $875M-$900M, vs. FactSet Est of $866.7M

MT Newswires Live
·
Oct 29, 2025

Ionis Pharmaceuticals reports $32 million in TRYNGOLZA net product sales for Q3 2025

Reuters
·
Oct 29, 2025

BRIEF-Ionis Pharmaceuticals Q3 Revenue USD 157 Million Vs. IBES Estimate USD 131.3 Million

Reuters
·
Oct 29, 2025

Ionis Reports Third Quarter 2025 Financial Results and Highlights Progress on Key Programs

THOMSON REUTERS
·
Oct 29, 2025

Ionis Pharmaceuticals Inc - Raises 2025 Revenue Guidance to $875-$900 Mln

THOMSON REUTERS
·
Oct 29, 2025

Ionis Pharmaceuticals Q3 Operating Income USD -160 Million

THOMSON REUTERS
·
Oct 29, 2025

Ionis Pharmaceuticals: Anticipate Growth in Product REV With Additional Partner REV to Position Co to Achieve Cash Flow Breakeven in 2028

THOMSON REUTERS
·
Oct 29, 2025

Intellia Therapeutics' Liver Toxicity Claim in Phase 3 Trials 'Unconvincing,' RBC Says

MT Newswires Live
·
Oct 28, 2025

Ionis Pharmaceuticals’ Orbit Study: A Promising Step for Rare Disease Treatment

TIPRANKS
·
Oct 28, 2025

Ionis Pharmaceuticals to Present Research at Oligonucleotide Therapeutics Society Annual Meeting

Reuters
·
Oct 21, 2025

Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares

Motley Fool
·
Oct 21, 2025

Ionis Pharmaceuticals (IONS): How Does Valuation Stack Up Following Revenue Surge and Upbeat 2025 Guidance?

Simply Wall St.
·
Oct 20, 2025

Ionis Pharmaceuticals EVP Brian Birchler Reports Sale of Common Shares

Reuters
·
Oct 17, 2025

Morgan Stanley Raises Price Target on Ionis Pharmaceuticals to $90 From $86, Keeps Overweight Rating

MT Newswires Live
·
Oct 16, 2025

Press Release: Ionis to hold third quarter 2025 financial results webcast

Dow Jones
·
Oct 16, 2025

TD Cowen Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Oct 10, 2025

Ionis, Jazz Named Top Picks as US Biopharma Heads Into Steady Q3, BofA Says

MT Newswires Live
·
Oct 09, 2025

Raymond James Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Oct 09, 2025